ALR2-IN-8
ALR2-IN-8 is a potent aldose reductase (ALR2/AKR1B1) inhibitor with a KI of 7.34 nM. ALR2-IN-8 has extremely low toxicity to normal cells and has a weak direct killing effect on cancer cells. ALR2-IN-8 can used for the studies of diabetic and inflammation-linked disorders[1].
Product Specifications
UNSPSC
12352100
Target
Aldose Reductase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease; Inflammation/Immunology
Smiles
O=C(OCC(OCC)=O)C1=CC=C(N(C(C2=C3C(Br)=C(Br)C(Br)=C2Br)=O)C3=O)C=C1
Molecular Formula
C19H11Br4NO6
Molecular Weight
668.91
References & Citations
[1]Zognjani B, et al. N-substituted phthalimide-carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: Synthesis, mechanistic insights, and cancer-relevant profiling. Bioorg Chem. 2025 Aug;163:108788.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040003-500 1x 500 µL
CD45RO (UCHL-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400977-500 1x 500 µL
TGF-beta (1D11.16.8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040460-100 1x 100 µL
CD44 Standard (156-3C11), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040679-100 1x 100 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470040-100 1x 100 µL
CD35 / CR1 (E11), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details